

# INDEX

## BIO-SCIENCE LAW REVIEW

### VOLUME 13

---

#### CONTENTS

Subject Index	i
Countries and Institutions	ii
Contributors	iv
Contributions	iv
Case List	v

---

#### Subject Index

##### COMPETITION

###### Dominance

Highest Italian administrative court has the final word on the *Xalatan* case and reinstates the original infringement decision of the Italian Competition Authority (Case Comment) 6 219

###### Pharmaceuticals

Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195

##### DEVELOPING COUNTRIES

###### Patents

Patents and access to medicine in the developing world: a call for broader engagement (Editorial) 3 87

##### DISCLOSURE

###### Clinical trial data

Transparency of clinical trial data: current state of play (Article) 6 204

##### EQUITY CAPITAL MARKETS

###### Capital raisings

Changes to facilitate capital raisings in UK markets (United Kingdom) 2 86

##### GENETIC RESOURCES

###### Regulation

Biodiversity laws: an emerging regulation on genetic resources or 'IP on life' through the backdoor? (Article) 4 119

##### GM CROPS

###### Authorisation

Legal considerations related to the authorisation, import and cultivation of GM crops in the European Union: a precedent for other regulated industries? (Editorial) 5 155

##### JURISDICTION

###### Infringement

UK Court of Appeal opens the way for pan-European jurisdiction on infringement  
*Actavis Group HF and Medis EHF v Eli Lilly and Company* (Case Comment) 2 71

##### MEDICINAL PRODUCTS

###### Licensing

Meeting the needs of patients: early access and adaptive licensing (Editorial) 6 191

###### Regulation

Falsified Medicines Directive (News) 1 27  
Protection for orphan medicinal products in the EU and controversies that have arisen under the EU regime (Article) 1 3

###### Unauthorised medicines

Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations (Article) 5 172

##### PATENTS

###### Access to medicine

Patents and access to medicine in the developing world: a call for broader engagement (Editorial) 3 87

###### Experts

Instructing experts in patent litigation (Article) 5 161

###### Gene patents

Isolated gene sequences and patentable subject-matter  
*Cancer Voices Australia v Myriad Genetics Inc* (News) 1 26  
Legal definition of human genes and patent eligibility in the light of the *Myriad* case (Article) 4 140  
US Supreme Court rules on BRCA1 and BRCA2 patents  
*Association of Molecular Pathology v Myriad Genetics* (Case Comment) 2 77

## **Infringement**

- Court of Appeal upholds the validity of Genentech patent  
(1) *Regeneron Pharmaceuticals Inc.* (2) *Bayer Pharma AG v Genentech Inc.* (Case Comment) 1 17
- Highest Italian administrative court has the final word on the *Xalatan* case and reinstates the original infringement decision of the Italian Competition Authority (Case Comment) 6 219
- UK IPO consultation on exemptions to patent infringement for clinical trials (Case Comment) 1 23

## **Injunctions**

- Teva's record of previous 'at risk' launches before patent expiry is deemed relevant to whether an injunction should be ordered against it  
*Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another* (Case Comment) 4 147

## **Patentability**

- CJEU reference on meaning of 'human embryos': does it include parthenotes?  
*International Stem Cell Corporation v Comptroller General of Patents* (Case Comment) 2 68
- Exceptions to patentability: *Australia v Europe* (Article) 2 49
- Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) (Case Comment) 1 21

## **Precursor cells**

- Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) (Case Comment) 1 21

## **Seeds**

- US Supreme Court: unanimous ruling leaves open questions with respect to other self replicating technology and the conditional sale doctrine  
*Bowman v Monsanto* (Case Comment) 2 74

## **Supplementary Protection Certificates**

- Recent European developments regarding supplementary protection certificates (Case Comment) 5 178
- Vaccines and SPCs: the CJEU reaches a fork in the road (Article) 2 35

## **Unified Patent Court**

- Unified Patent Court – shifting to a new paradigm (Article) 1 9
- Unified Patent Court: the 16th draft rules of procedure: ten key developments (Case Comment) 6 215

## **Validity**

- Alzheimer's patent invalid for insufficiency – patents must be more than merely 'research projects'  
*Eli Lilly and Co v Janssen Alzheimer Immunotherapy* (Case Comment) 3 112
- Court of Appeal upholds the validity of Genentech patent  
(1) *Regeneron Pharmaceuticals Inc.* (2) *Bayer Pharma AG v Genentech Inc.* (Case Comment) 1 17

## **PHARMACEUTICALS**

### **Competition**

- Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195

## **Paediatric Regulation**

- Better medicines for children? What have been the benefits and lessons learned after five years of the Paediatric Regulation? (Article) 3 95

## **Pricing**

- UK Pharmaceutical Price Regulation Scheme (PPRS) and the statutory regulations: an overview and outline of how the schemes may impact the life sciences industry (Case Comment) 6 208

## **Unauthorised medicines**

- Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations (Article) 5 172

## **PLANT VARIETIES**

### **Protection regimes**

- Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications (Article) 3 101

## **TAX**

- New tax measures for 2013 offer tax saving opportunities for life sciences companies (UK News) 1 29

## **TECHNOLOGY AGREEMENTS**

### **Licensing**

- Changes to technology licensing in Europe: new competition law analysis will affect existing licences and new negotiations (Article) 3 90

## **TRADE SECRETS**

### **EU Directive**

- Uniform trade secrets protection for Europe? (Case Comment) 5 184

## **Countries and Institutions**

### **AUSTRALIA**

#### **Patentability**

- Exceptions to patentability: *Australia v Europe* (Article) 2 49

#### **Patents**

- Isolated gene sequences and patentable subject-matter  
*Cancer Voices Australia v Myriad Genetics Inc* (News) 1 26

### **BURKINA FASO**

#### **Plant variety protection**

- Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications (Article) 3 101

**COURT OF JUSTICE OF THE EUROPEAN UNION (CJEU)****Patents**

- Recent European developments regarding supplementary protection certificates (Case Comment) 5 178
- Vaccines and SPCs: the CJEU reaches a fork in the road (Article) 2 35

**EUROPEAN COMMISSION****Competition law**

- Changes to technology licensing in Europe: new competition law analysis will affect existing licences and new negotiations (Article) 3 90

**Paediatric Regulation**

- Better medicines for children? What have been the benefits and lessons learned after five years of the Paediatric Regulation? (Article) 3 95

**Trade secrets**

- Uniform trade secrets protection for Europe? (Case Comment) 5 184

**EUROPEAN UNION****Disclosure**

- Transparency of clinical trial data: current state of play (Article) 6 204

**Genetic resources**

- Biodiversity laws: an emerging regulation on genetic resources or 'IP on life' through the backdoor? (Article) 4 119

**GM crops**

- Legal considerations related to the authorisation, import and cultivation of GM crops in the European Union: a precedent for other regulated industries? (Editorial) 5 155

**Medicinal products**

- Falsified Medicines Directive (News) 1 27
- Meeting the needs of patients: early access and adaptive licensing (Editorial) 6 191
- Protection for orphan medicinal products in the EU and controversies that have arisen under the EU regime (Article) 1 3

**Patents**

- Exceptions to patentability: Australia v Europe (Article) 2 49
- Unified Patent Court – shifting to a new paradigm (Article) 1 9
- Unified Patent Court: the 16th draft rules of procedure: ten key developments (Case Comment) 6 215

**Pharmaceuticals**

- Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195
- Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations (Article) 5 172

**GERMANY****Patents**

- Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) (Case Comment) 1 21

**ITALY****Competition**

- Highest Italian administrative court has the final word on the *Xalatan* case and reinstates the original infringement decision of the Italian Competition Authority (Case Comment) 6 219

**TANZANIA****Plant variety protection**

- Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications (Article) 3 101

**UNITED KINGDOM****Injunctions**

- Teva's record of previous 'at risk' launches before patent expiry is deemed relevant to whether an injunction should be ordered against it  
*Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another* (Case Comment) 4 147

**Jurisdiction**

- UK Court of Appeal opens the way for pan-European jurisdiction on infringement  
*Actavis Group HF and Medis EHF v Eli Lilly and Company* (Case Comment) 2 71

**Medicinal products**

- Falsified Medicines Directive (News) 1 27

**Patents**

- Alzheimer's patent invalid for insufficiency – patents must be more than merely 'research projects'  
*Eli Lilly and Co v Janssen Alzheimer Immunotherapy* (Case Comment) 3 112
- CJEU reference on meaning of 'human embryos': does it include parthenotes? *International Stem Cell Corporation v Comptroller General of Patents* (Case Comment) 2 68
- Court of Appeal upholds the validity of Genentech patent  
*(1) Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v Genentech Inc.* (Case Comment) 1 17
- Instructing experts in patent litigation (Article) 5 161
- UK IPO consultation on exemptions to patent infringement for clinical trials (Case Comment) 1 23

**Pharmaceuticals**

- UK Pharmaceutical Price Regulation Scheme (PPRS) and the statutory regulations: an overview and outline of how the schemes may impact the life sciences industry (Case Comment) 6 208

**Tax**

- New tax measures for 2013 offer tax saving opportunities for life sciences companies (News) 1 29

**UNITED STATES****Patents**

- Legal definition of human genes and patent eligibility in the light of the *Myriad* case (Article) 4 140
- US Supreme Court rules on BRCA1 and BRCA2 patents  
*Association of Molecular Pathology v Myriad Genetics* (Case Comment) 2 77
- US Supreme Court: unanimous ruling leaves open questions with respect to other self replicating technology and the conditional sale doctrine  
*Bowman v Monsanto* (Case Comment) 2 74

**Pharmaceuticals**

- Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law (Article) 6 195

## Contributors

Abrahams, Darren (Editorial) 5 155  
 Balfour, Laura (Article) 3 90  
 Ball, Jonathan (Case Comment) 4 147  
 Berghe, Pascal (Article) 5 172  
 Blakeney, Michael (Book Review) 2 79  
 Brindley, Conor (News) 1 29  
 Cline, Helen (Case Comment) 6 208  
 Cohen, Simon (Articles) 2 35, 5 161  
 Cook, Trevor (Article) 1 3  
 Cox, David (News) 1 26  
 Curley, Duncan (Book Review) 1 31  
 De Jonge, Bram (Article) 3 101  
 Del-Greco, Joseph (Article) 6 195  
 Dodds-Smith, Ian (Article) 6 204  
 Douma, Tjibbe (Case Comment) 5 178  
 England, Paul (Articles) 2 35, 5 161; (Case Comments) 5 184, 6 215  
 Farmer, Stacey (Case Comment) 1 21  
 Fullwood, Louise (News) 1 27  
 Giannino, Michele (Case Comment) 6 219  
 Gilbert, Penny (Case Comment) 2 71  
 Grund, Martin (Case Comment) 1 21  
 Herrlinger, Christoph (Article) 4 119  
 Hill, Christian (Case Comment) 6 208  
 Jones, Nigel (Editorial) 3 87; (Book Review) 4 151  
 Kailasanath, Vinita (Case Comments) 2 74, 2 77  
 Kapetanaki, Natalia A (Article) 4 140  
 Kempton, Luke (Case Comment) 1 23  
 Kempton, Nick (Case Comment) 2 71  
 Killick, James (Article) 5 172  
 Kock, Michael A (Article) 4 119  
 Kokke, Margot (Case Comment) 5 178  
 Kuipers, Gertjan (Case Comment) 5 178  
 Lambrix, Ellen (Article) 3 90  
 Mahop, Marcelin Tonye (Article) 3 101  
 Mester, Gabor (Case Comment) 1 21  
 Middlemiss, Susie (Article) 3 90  
 Mills, Oliver (Article) 2 49  
 Mulryne, Jackie (Article) 6 204  
 Munyi, Peter (Article) 3 101  
 Nickless, David (Case Comment) 3 112  
 O'Leary, Julianne (Article) 6 195  
 O'Sullivan, Nina (Case Comments) 1 17, 2 68  
 Ranson, Paul (Editorial) 6 191; (Case Comment) 6 208  
 Rhodes, Daniel (Book Review) 4 151  
 Roberts, Tim (Book Reviews) 2 82, 3 115  
 Sant, David (Article) 1 9  
 Strachan, Grant (Article) 3 95

## Contributions

### EDITORIALS

Legal considerations related to the authorisation, import and cultivation of GM crops in the European Union: a precedent for other regulated industries? *Darren Abrahams* 5 155  
 Meeting the needs of patients: early access and adaptive licensing *Paul Ranson* 6 191  
 Patents and access to medicine in the developing world: a call for broader engagement *Nigel Jones* 3 87

## ARTICLES

Better medicines for children? What have been the benefits and lessons learned after five years of the Paediatric Regulation? *Grant Strachan* 3 95  
 Biodiversity laws: an emerging regulation on genetic resources or 'IP on life' through the backdoor? *Christoph Herrlinger and Michael A Kock* 4 119  
 Changes to technology licensing in Europe: new competition law analysis will affect existing licences and new negotiations *Laura Balfour, Ellen Lambrix and Susie Middlemiss* 3 90  
 Exceptions to patentability: Australia v Europe *Dr Oliver Mills* 2 49  
 Instructing experts in patent litigation *Simon Cohen and Paul England* 5 161  
 Legal definition of human genes and patent eligibility in the light of the *Myriad* case *Natalia A Kapetanaki* 4 140  
 Plant variety protection regimes and seed regulations in Sub-Saharan Africa: current trends and implications *Marcelin Tonye Mahop, Bram de Jonge and Peter Munyi* 3 101  
 Protection for orphan medicinal products in the EU and controversies that have arisen under the EU regime *Trevor Cook* 1 3  
 Reverse payment settlement agreements in the pharmaceutical industry: settling the debate between the pro-exclusivity principles of patent law and the pro-competition principles of antitrust law *Julianne O'Leary and Joseph Del-Greco* 6 195  
 Should cost prevail over safety? The risks of promoting unauthorised pharmaceuticals and off-label use for budgetary considerations *James Killick and Pascal Berghe* 5 172  
 Transparency of clinical trial data: current state of play *Ian Dodds-Smith and Jackie Mulryne* 6 204  
 Unified Patent Court – shifting to a new paradigm *David Sant* 1 9  
 Vaccines and SPCs: the CJEU reaches a fork in the road *Simon Cohen and Paul England* 2 35

## CASE COMMENTS

Alzheimer's patent invalid for insufficiency – patents must be more than merely 'research projects' *Eli Lilly and Co v Janssen Alzheimer Immunotherapy, David Nickless* 3 112  
 CJEU reference on meaning of 'human embryos': does it include parthenotes? *International Stem Cell Corporation v Comptroller General of Patents, Nina O' Sullivan* 2 68  
 Court of Appeal upholds the validity of Genentech patent (1) *Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v Genentech Inc., Nina O' Sullivan* 1 17  
 Highest Italian administrative court has the final word on the *Xalatan* case and reinstates the original infringement decision of the Italian Competition Authority *Michele Giannino* 6 219  
 Neural precursor cells II: decision of the German Supreme Court (Bundesgerichtshof) X ZR 58/07 (Brüstle/Greenpeace) *Dr Gabor Mester, Dr Stacey Farmer and Dr Martin Grund* 1 21  
 Recent European developments regarding supplementary protection certificates *Gertjan Kuipers, Tjibbe Douma and Margot Kokke* 5 178  
 Teva's record of previous 'at risk' launches before patent expiry is deemed relevant to whether an injunction should be ordered against it *Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another, Jonathan Ball* 4 147

- UK Court of Appeal opens the way for pan-European jurisdiction on infringement *Actavis Group HF and Medis EHF v Eli Lilly and Company, Nick Kempton and Penny Gilbert* 2 71
- UK IPO consultation on exemptions to patent infringement for clinical trials *Luke Kempton* 1 23
- UK Pharmaceutical Price Regulation Scheme (PPRS) and the statutory regulations: an overview and outline of how the schemes may impact the life sciences industry *Christian Hill, Paul Ranson and Helen Cline* 6 208
- Unified Patent Court: the 16th draft rules of procedure: ten key developments *Paul England* 6 215
- Uniform trade secrets protection for Europe? *Paul England* 5 184
- US Supreme Court rules on BRCA1 and BRCA2 patents *Association of Molecular Pathology v Myriad Genetics, Vinita Kailasanath* 2 77
- US Supreme Court: unanimous ruling leaves open questions with respect to other self replicating technology and the conditional sale doctrine *Bowman v Monsanto, Vinita Kailasanath* 2 74

## BOOK REVIEWS

- All That Matters – Bioethics (Donna Dickenson)  
*Tim Roberts* 2 82
- Crop Genetic Resources as a Global Commons. Challenges in International Law and Governance (Michael Halewood, Isabel Lopez Noriega and Selim Louafi, eds) *Michael Blakeney* 2 79
- Medical Law – A Very Short Introduction (Charles Foster)  
*Tim Roberts* 3 115
- Pharmaceutical Innovation, Competition and Patent Law – A Trilateral Perspective (Josef Drexler and Nari Lee, eds)  
*Nigel Jones and Daniel Rhodes* 4 151
- Pharmaceutical, Biotechnology and Chemical Inventions – World Protection and Exploitation (Duncan Bucknell, ed., et al.)  
*Dr Duncan Curley* 1 31

## Case List

- Actavis v Sanofi (CJEU) Case C-443/12 5 178
- Actavis Group HF and Medis EHF v Eli Lilly and Company [2013] EWCA Civ 517 2 71
- Association of Molecular Pathology v Myriad Genetics (United States) June 13, 2013 569 U.S. \_\_\_ (2013) slip.op. at 1 2 77, 4 141
- Bowman v Monsanto (United States) May 13, 2013 569 U.S. \_\_\_ (2013) slip.op. 2 74
- Cancer Voices Australia v Myriad Genetics Inc (Australia) [2013] FCA 65 1 26
- Eli Lilly v HGS (CJEU) Case C-493/12 5 178
- Eli Lilly and Co v Janssen Alzheimer Immunotherapy [2013] EWHC 1737 (Pat) 3 112
- FTC v Actavis, Inc. (United States) 133 S.Ct. 2223 (2013) 6 195
- Georgetown II (CJEU) Case C-484/12 5 178
- GlaxoSmithKlein Biological SA v Comptroller-General of Patents, Designs and Trade Marks [2013] EWHC 619 (Pat) 2 35
- In the matter of Dr Oliver Brüstle v Greenpeace e.V. (Germany) Bundesgerichtshof X ZR 58/07 1 21
- Italian Competition Authority (Autorità Garante della Concorrenza e del Mercato) v Pfizer et al. (Italian Supreme Administrative Court) Case 693/2014 12 February 2014 6 219
- Lundbeck (European Commission) Case COMP/AT.39226 19 June 2013 6 195
- Merck Sharp Dohme Corp and Another v Teva Pharma BV and Another [2013] EWHC 1958 (Pat) 9 July 2013 4 147
- Oliver Brüstle v Greenpeace e.V. (CJEU) Case C-34/10 [2012] CMLR 41 2 68
- Pioneer Hi-Bred International, Inc v Commission (EGC) Case T164/10 5 155
- (1) Regeneron Pharmaceuticals Inc. (2) Bayer Pharma AG v Genentech Inc. [2013] EWCA Civ 93 1 17
- International Stem Cell Corporation v Comptroller General of Patents [2013] EWHC 807 (Ch) 2 68

